Just checked out #SITC Member Brian Rini, MD from UCDavisMedSchool present the long-term results from the KEYNOTE-426 trial of immuno-based combination therapy for kidney cancer at #ASCO23 ASCO. Kidney Cancer #kidneycancer #CIM23 #WearWhite #Immune2Cancer #SITC 23
You can't quite see me because I am about 250 miles southwest from where this photo was taken, but I am part of this great family of colleagues. 👋 🔍 Good to see you all from afar!
#CIM23 #Immune2Cancer #WearWhite #immunotherapy #JITC
#ICYMI : Hussein Tawbi, MD, PhD (of MD Anderson Cancer Center) et al reported the exploratory biomarker analyses from the phase 3 trial of COMBI-i in #JITC . Check it out > bit.ly/43CLcvi > then head over to see him present 2-year results from the RELATIVITY-047 trial at #ASCO23 . #CIM23
SITC’s strength is in its members! The society provides the unique opportunity to connect with professionals in each sector of the immunotherapy field. #CIM23 #WearWhite #Immune2Cancer
I wear white for my #breastcancer patients who need more #immunotherapy options. June is #CancerImmunotherapyMonth #CIM23 Pelotonia Institute for Immuno-Oncology Pelotonia The James Ohio State Medical Oncology why do you wear white?
In honor of #CIM23 , we hope you will follow and share our daily posts celebrating the #SITC members and initiatives that are driving the #CancerIO field forward! #WearWhite #Immune2Cancer - Learn more: sitcancer.org/aboutsitc/medi…
#DYK that Society for Immunotherapy of Cancer & National Cancer Institute are kicking off the Computational #ImmunoOncology Webinar Series on June 28 at 12:30pm ET? sitcancer.org/education/webi… #CIM23
Learn more about National Cancer Institute #FundingOpportunity that supports planning and feasibility studies to integrate cancer #healthdisparities into #ImmunoOncology research: grants.nih.gov/grants/guide/r… #CIM23
Just caught a great session at #ASCO23 with Dr. Harriet M. Kluger from Yale School of Medicine and Siwen Hu-Lieskovan from Huntsman Cancer Institute, discussing their insights on resistance to #immunotherapy , biomarkers and combination therapies. Very insightful. #SITC23 #CIM23 #Immune2Cancer ASCO
SAVE THE DATE: The 2023 Society for Immunotherapy of Cancer & National Cancer Institute Computational #ImmunoOncology Webinar Series starts on June 28 at 12:30pm ET! Learn more: sitcancer.org/education/webi… #CIM23
June is Cancer #Immunotherapy Month, a global initiative that we are proud to have supported annually.🎗️
During the month we’ll be highlighting several important #ImmunoOncology educational scientific programs and technologies.
➡️ bit.ly/3CdSt9a
#Immune2Cancer #CIM23
#ASCO23 | We caught up with Claire Roddie of UCL Cancer Institute, who shared some results from the FELIX trial, which is evaluating the safety & efficacy of obe-cel in R/R adult B-ALL.
Watch:
👉 ow.ly/JfaB50OHBeB 👈
ASCO #HemOnc #Leusm #ALLsm #ImmunoOnc #CARTcell #CIM23